共 77 条
- [1] Day C-P(2015)Preclinical mouse cancer models: a maze of opportunities and challenges Cell 163 39-53
- [2] Merlino G(2017)Genetically engineered mouse models in oncology research and cancer medicine EMBO Mol. Med. 9 137-153
- [3] Van Dyke T(2016)Loss of PTEN promotes resistance to T cell-mediated immunotherapy Cancer Discov. 6 202-216
- [4] Kersten K(2017)Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery Cancer Immunol. Res. 5 29-41
- [5] de Visser KE(2018)Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments PLoS ONE 13 e0206223-489
- [6] van Miltenburg MH(2013)Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy J. Immunother. 36 477-1391
- [7] Jonkers J(2018)The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent Front. Immunol. 9 2100-54787
- [8] Peng W(2018)Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains Cancer Immunol. Immunother. 67 1381-3360
- [9] Mosely SIS(2017)Tumor location impacts immune response in mouse models of colon cancer Oncotarget 8 54775-175
- [10] Yu JW(2019)The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy J. Clin. Invest. 129 3347-369